LEXICON PHARMACEUTICAL

New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

05 Nov 2022 09:35:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

04 Nov 2022 07:58:00 By Nasdaq GlobeNewswire

New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022

31 Oct 2022 07:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

24 Oct 2022 07:59:00 By Nasdaq GlobeNewswire

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

02 Oct 2022 12:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

20 Sep 2022 07:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease

22 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

05 Aug 2022 15:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

02 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

29 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

28 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

Lexicon Announces Proposed Public Offering Of Common Stock

27 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

27 Jul 2022 06:59:00 By Nasdaq GlobeNewswire

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

29 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference

01 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure

31 May 2022 07:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update

05 May 2022 05:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022

29 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference

07 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Lexicon Welcomes New Guidelines for the Management of Heart Failure

04 Apr 2022 07:00:01 By Nasdaq GlobeNewswire